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ABSTRACT
The present study was performed to determine the effects of central
administration of leptin on food intake and sympathetic nervous
system activity in a nonrodent species, the rhesus monkey. Peripheral
administration of leptin at doses (1 and 3 mg/kg, sc) that produced
increments of circulating leptin concentrations within a physiological
range did not inhibit food intake over the subsequent 3 days. In
contrast, leptin (1 mg/kg, intracerebroventricularly) had no acute ef-
fect on food intake, but caused a significant and sustained suppression
(40–50%) of food intake during the entire following day (P , 0.01). In
addition, circulating norepinephrine levels increased by 55 6 16%
(P , 0.02) 1 h after intracerebroventricular leptin administration, but
did not increase after artificial cerebrospinal fluid administration.
These results indicate that leptin can provide a signal to the central
nervous system that decreases food intake in primates and in addition
acutely activates the sympathetic nervous system. However, the re-
sults showing an acute increase in circulating leptin concentrations
after peripheral administration of human leptin suggest that in pri-
mates, increases in circulating leptin within the physiological range
do not acutely regulate food intake. Leptin may be more important in
regulating food intake when there are sustained changes in circulat-
ing concentrations of leptin (e.g. with obesity, prolonged energy re-
striction, or diabetes). (J Clin Endocrinol Metab 84: 711–717, 1999)
LEPTIN, a hormone produced by adipocytes, is believedto play an important role in the regulation of body
adiposity by acting at the level of the central nervous system
to modulate both food intake and energy expenditure (1, 2).
The original evidence for these actions of leptin came from
studies in which exogenous hormone was administered to
ob/ob mice, a strain with a defect in the gene that encodes for
leptin (3–5). The ob/ob mice are markedly obese and hy-
perphagic. Administration of exogenous leptin to ob/ob mice
reduces food intake, increases energy expenditure, and re-
sults in dramatic decreases in body weight (3–5). Congenital
leptin deficiency or defects in its receptor leading to extreme
early onset obesity have recently been reported in humans (6,
7). Although circulating leptin concentrations are closely re-
lated to body adiposity (1, 8–10), a dynamic role for leptin in
the regulation of food intake and energy expenditure has
been suggested by the finding that circulating leptin con-
centrations decrease during fasting (9, 10) or energy restric-
tion (11) and increase after refeeding (9, 12). In addition,
circulating leptin concentrations exhibit a diurnal pattern
(13–15) with a nocturnal peak that is entrained by meal
timing (16). Furthermore, insulin infusions that produce
physiological increments in plasma insulin increase circu-
lating leptin concentrations in human subjects (17). Lastly,
24-h leptin concentrations are increased in subjects consum-
ing high carbohydrate meals, which enhance insulin secre-
tion (18), an effect that may be mediated by increased adi-
pocyte glucose metabolism (19).
Administration of exogenous leptin or activation of the
gene that encodes for leptin in normal mice and rats has been
shown to effectively decrease food intake, increase energy
expenditure, and result in body weight loss (3, 4, 20–22).
However, despite the wealth of data collected over the past
2 yr on these effects of leptin in rodents, several critical issues
remain unresolved. First, very few of the studies adminis-
tering leptin have measured the plasma levels created by
exogenous hormone administration, and those that have in-
dicate that most published studies have examined the effects
of pharmacological doses of this hormone. Thus, we do not
know whether the physiological changes in circulating leptin
levels that occur with meal consumption and brief periods of
fasting have a role in regulating food intake and energy
expenditure. Second, there have been no reports to date of
regulation of food intake and energy expenditure by leptin
in nonrodent species; thus, the applicability of findings in
rodents to the control of food intake and energy expenditure
in nonrodent species has not been established.
Several lines of evidence indicate that in rodents, leptin
appears to exert its actions on food intake and energy ex-
penditure by acting at the level of the central nervous system.
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Receptors for leptin have been localized within several brain
areas, importantly in hypothalamic regions including the
paraventricular nucleus and the arcuate nucleus, that are
known to be areas important in the control of food intake
(23–26). Moreover, administration of leptin systemically has
been shown to activate neurons in these regions, as indicated
by increased expression of Fos (27). Leptin receptors have
been colocalized in neuropeptide Y (NPY) neurons in rodents
(23) as well as in nonhuman primates (28). Leptin decreases
the synthesis and release of NPY, a hypothalamic neuropep-
tide known to be a potent stimulator of food intake (29–31).
Leptin administration intracerebroventricularly (icv) can de-
crease food intake and increase energy expenditure in rats
(20, 25, 31–33). Perhaps most convincingly, several studies
have shown that microinjection of leptin into the ventrome-
dial hypothalamus (34) and the arcuate nucleus (35) can
potently decrease food intake in the rat. A report by Collins
et al. (36) showing that norepinephrine turnover in brown fat
is increased soon after leptin administration, before an effect
of leptin on food intake, suggests that leptin-induced in-
creases in energy expenditure may at least in part reflect an
activation of the sympathetic nervous system. This has been
supported by the finding that leptin increases the firing rates
of sympathetic nerves in rats (37).
The first goal the of the present study was to determine
whether administering leptin at doses that produce acute
increases in circulating leptin concentrations within the
physiological range decreases food intake in rhesus mon-
keys. The second goal was to determine whether leptin ad-
ministered directly into the central nervous system (icv into
the third ventricle) is effective in regulating food intake and
sympathetic nervous system activity in primates.
Materials and Methods
Animals
Sixteen adult male rhesus monkeys, weighing 9.6–13.5 kg, were used
for these studies. Monkeys were housed in individual cages in a tem-
perature-controlled room (24 6 2 C) with lights on 12 h each day
(0700–1900 h). Monkeys were maintained on a standard ad libitum feed-
ing regimen, with two meals each day at 0900 and 1600 h, consisting of
1100 Cal (20 biscuits) of Purina High Protein Monkey Diet, jumbo size
(no. 5047, Ralston Purina, St. Louis MO) and one quarter piece of fresh
fruit at the morning meal. Before the initiation of experiments, monkeys
had been adapted for at least 6 weeks to this feeding schedule, and their
food intake was stable. Water was available at all times ad libitum. The
studies were reviewed and approved by the institutional animal care
and use committee of the Oregon Regional Primate Research Center.
Catheterization procedure
Five monkeys had a subclavian venous catheter and a third cere-
broventricular cannula implanted at least 2 months before these exper-
iments. The venous catheter was implanted using standard sterile sur-
gical procedures, and monkeys were maintained on jacket/tether/
swivel systems, as described previously (38).
Before placement of the third ventricular cannula, monkeys were
anesthetized [with ;20 mg/kg Nembutal (Abbott Laboratories, North
Chicago, IL)] and placed in a stereotaxic frame. The ventricular system
was visualized by radiograph after injection of 300 mL of a radioopaque
solution (Omnipaque, Winthrop Pharmaceuticals, New York, NY) into
the lateral ventricle. Based on this radiograph, the third ventricular
cannula was lowered into position through a second hole in the skull,
so that the tip of the cannula was in the lower third of the third ventricle,
above the median eminence. Placement of the cannula was confirmed
by radiograph subsequent to an injection of 50 mL Omnipaque. The top
portion of the cannula was adhered to the skull with dental acrylic. A
catheter of polyethylene tubing (PE 50, Becton Dickinson and Co., Par-
sippany NJ), filled with artificial cerebrospinal fluid (aCSF; composed of
0.166 g/L CaCl2, 7.014 g/L NaCl, 0.298 g/L KCl, 0.203 g/L MgCl2z6H2O,
and 2.10 g/L NaHCO3; Life Technologies, Grand Island, NY) was at-
tached to the cannula and tunneled sc to exit with the venous catheter
between the scapulae. The ventricular cannula was passed through the
same tether as the venous catheter and was kept patent with a constant
infusion of aCSF at a rate of approximately 600 mL/24 h.
Blood-sampling procedures
Blood samples were collected via indwelling venous catheters into
sterile heparinized syringes. Samples for measurement of leptin were
transferred into sterile glass tubes and kept cold until centrifugation.
Samples for measurement of catecholamines were transferred into ice-
cold glass tubes containing 2.25 mg ethyleneglycol-bis-(b-aminoethyl
ether)-N,N,N9,N9-tetraacetic acid and 1.5 mg reduced glutathione and
centrifuged immediately. Both samples were centrifuged at 2400 rpm for
10 min. The red blood cells from the leptin samples were resuspended
in sterile saline and reinfused through the indwelling venous catheters.
The plasma from the catecholamine samples was placed in Eppendorf vials
immediately after centrifugation, snap-frozen, and stored at 280 C.
Experimental protocols
Exp 1. To determine whether normal physiological variations in plasma
leptin concentrations play a role in acutely regulating food intake in
rhesus monkeys, leptin (Linco Research, Inc., St. Charles, MO) or saline
was administered via sc injection to 10 noncatheterized monkeys, and
food intake was measured for the subsequent 3 days. Before this study,
a pilot study was performed with five catheterized monkeys to deter-
mine the time course and magnitude of fluctuations in leptin secretion
across the 24-h day on the same ad libitum feeding regimen. We found
that maximal plasma leptin concentrations occurred between 2300–0400
h and were about 2-fold greater than the minimum daily plasma leptin
concentrations. Thus, to examine the effects of systemic leptin admin-
istration on food intake, we chose to enhance the magnitude of the
endogenous nighttime rise in plasma leptin concentrations by injecting
a dose of 3 mg/kg leptin at 0130 h and monitoring food intake for 3 days.
The leptin dose was based on the results from another study in our
laboratory in which adult male rhesus monkeys were given sc injections
of leptin at 1 and 3 mg/kg at 0130 h (Cameron, J. L., and P. J. Havel,
unpublished data). Lastly, we repeated this study, injecting 3 mg/kg
leptin, sc, to monkeys at 1600 h and monitoring food intake for 3 days.
Exp 2. The second experiment was performed to examine the effects of
icv injection of leptin on food intake and plasma catecholamines. Five
monkeys with indwelling icv and venous catheters were studied twice,
once after the administration of leptin (1 mg/kg in 20 mL aCSF, icv) and
once after the administration of aCSF (icv). For this experiment, recom-
binant human leptin was purchased from Linco Research, Inc. Each of
the two studies was conducted over a 3-day period. On day 1, a bolus
icv injection (leptin or aCSF) was given at 1600 h, at the same time that
the afternoon meal was provided. Food intake was monitored by count-
ing remaining biscuits at 30, 60, 90, 120, and 240 min after the meal was
provided and the following morning before the morning meal. Food
intake continued to be monitored in a similar fashion after both the
morning and afternoon meals on the second and third days of the study.
Blood samples were collected at 15-min intervals for the first 12 h after
the meal and at 30-min intervals for the following 2 h; one more blood
sample was collected the following morning.
Assays
Plasma leptin concentrations were measured with a sensitive RIA for
primate leptin with reagents supplied by Linco Research, Inc. Plasma
norepinephrine and epinephrine were measured in duplicate with a
highly sensitive and specific radioenzymatic assay (39). The intra- and
interassay coefficients of variation for the plasma catecholamine assay
were 6% and 12%, respectively.
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Data analyses
In each experiment, monkeys were studied twice, once after leptin
administration and once after administration of vehicle (aCSF or saline).
Food intake and plasma hormone and neurotransmitter responses were
compared at each time point using paired one-tailed Student’s t test. P #
0.05 was considered significant.
Results
Effect of systemic leptin administration on food intake
In our pilot study to determine the time course of leptin
secretion in male monkeys across the 24-h day, we found that
maximal plasma leptin concentrations occurred between
2300–0400 h and were about 2-fold greater than the mini-
mum daily plasma leptin concentrations (Fig. 1). To augment
the nocturnal rise in plasma leptin levels that occurs over the
course of a normal day, we chose to administer a 3 mg/kg
dose of leptin, sc. This dose was based on the results from a
pilot study in our laboratory in which four adult male rhesus
monkeys were given sc injections of leptin at doses of 1 and
3 mg/kg (Cameron, J. L., and P. J. Havel, unpublished data).
Figure 2 shows the increase in circulating leptin that occurred
after injection of leptin at doses of 1 and 3 mg/kg leptin given
as an sc injection at 0130 h (the time at which peak levels in
circulating leptin normally occur during the 24-h day). Lep-
tin administration at 1 and 3 mg/kg induced increases in
plasma leptin more than 2- and 3-fold, respectively, over
baseline fasting concentrations in all four monkeys used in
the pilot experiment. Increased plasma leptin concentrations
lasted for more than 8 h after leptin administration. How-
ever, in Exp 1 we found that leptin administered at a dose of
3 mg/kg at 0130 h had no effect on food intake in the 10
monkeys studied either acutely or during the succeeding 3
days (Fig. 3). Lastly, to examine the effect of systemic leptin
administration on food intake at a time when leptin concen-
trations are normally low, we administered leptin (3 mg/kg,
sc) to 10 monkeys at 1600 h, but similar to leptin adminis-
tration at 0130 h, there was no effect on food intake either
acutely or for the succeeding 3 days (data not shown).
Effect of central leptin administration on food intake
Central administration of leptin (1 mg/kg) had no imme-
diate effect on food intake (i.e. the day 1 afternoon meal; Fig.
4). However, leptin treatment reduced food intake by 40–
50% throughout the period of morning meal consumption
compared to that during the control study when aCSF alone
was administered. None of the animals exhibited more than
a 66% decrease in food intake after central leptin adminis-
tration. This reduction of food intake lasted into the after-
noon meal on day 2. On day 3, food intake was generally
normal, and on day 4 it was completely normal. Plasma
leptin concentrations were slightly, but not significantly,
higher on the day of leptin vs. the day of aCSF treatment.
FIG. 1. Mean plasma leptin concentrations in five monkeys on a day
of normal food intake (a morning meal at 0930 h and an afternoon
meal at 1600 h). Blood samples were collected hourly. The shaded area
depicts the SEM. Lights were on from 0700–1900 h, as indicated by the
black bar.
FIG. 2. Plasma leptin concentrations in a monkey fasted for 24 h and
then given a sc injection of 1 mg/kg (open circles) or 3 mg/kg (closed
circles) recombinant human leptin.
FIG. 3. Food intake over four meals in 10 monkeys after a single sc
injection of either vehicle (open circles) or human leptin (3 mg/kg;
closed circles) at 0130 h before day 1. Data are shown as the mean
(SEM).
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Plasma leptin did not increase after icv leptin administration
and was not different during the 4-h postinjection period
between the leptin and aCSF treatment days.
Effect of central leptin on plasma catecholamines
When monkeys received leptin (1 mg/kg, icv), there was
an acute increase in circulating norepinephrine concentra-
tions, with levels increasing from a baseline of 254 6 50 to
396 6 81 pg/mL [change (D), 1142 6 41 pg/mL; %D, 155 6
16%; both P , 0.02] at 1 h after administration (Fig. 5). In
contrast, plasma norepinephrine did not increase signifi-
cantly after intracerebroventricular administration of aCSF,
averaging 256 6 53 pg/mL before and 290 6 54 pg/mL 1 h
after injection [D, 134 6 20 pg/mL (P 5 NS); %D, 115 6 9%
(P 5 NS)]. By the following morning, circulating norepi-
nephrine levels had decreased and were similar during the
leptin and aCSF trials. Circulating plasma epinephrine con-
centrations were unaffected by either leptin or aCSF admin-
istration, averaging 95 6 30 pg/mL before and 100 6 28
pg/mL 1 h after leptin administration and 95 6 13 pg/mL
before and 92 6 28 pg/mL 1 h after aCSF treatment.
Discussion
Subcutaneous administration at doses designed to pro-
duce increments in circulating plasma leptin concentrations
within the normal physiological range did not suppress food
intake either acutely or during several subsequent meals. In
our first study, leptin was administered at 0130 h to enhance
the magnitude of the normal diurnal peak in leptin that
occurs in the middle of the night. A similar diurnal pattern,
with peak levels occurring at night, has been reported in
humans (13–16), and it has been hypothesized that increased
levels of leptin occurring at night may prevent individuals
from awakening from hunger and may serve to limit food
intake during the morning meal (1). Our results do not sup-
port such a role in rhesus monkeys, in that the 3 mg/kg
injection of leptin would have raised circulating leptin con-
centrations by 3-fold above normal nighttime levels for 6–9
h, yet there was no suppression of food intake during the
morning meal.
We subsequently wondered whether an effect of leptin on
food intake would be more readily apparent if leptin was
administered at a time of day when endogenous leptin levels
are low. Leptin was administered systemically at 1600 h, a
time at which we found that icv leptin administration was
effective in suppressing food intake during the following
day. However, administration of leptin at this time did not
inhibit subsequent food intake. Our results suggest that in-
creases in leptin that occur over the course of a normal day
do not play a role in acutely regulating the magnitude of
daily food intake in rhesus monkeys. This is the first study
to our knowledge to examine the effects of leptin, within the
physiological range, on food intake in primates. Most of the
studies published to date that have documented suppression
FIG. 5. The change in plasma norepinephrine (picograms per mL)
concentrations in response to leptin or aCSF during the first hour
postadministration. Data are shown as the mean (SEM). The asterisk
indicates a significant difference between vehicle and leptin trials
(P , 0.02).
FIG. 4. Food intake (grams) over five
meals in five monkeys after a single icv
injection of either aCSF (open circles) or
human leptin (1 mg/kg; closed circles) on
day 1 at 1600 h. Data are shown as the
mean 6 SEM. Asterisks indicate a sig-
nificant difference between vehicle and
leptin trials (P , 0.05).
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of food intake after systemic administration of leptin have
used leptin-deficient ob/ob mice, animals that exhibit en-
hanced sensitivity to leptin (40) or have used very large doses
of leptin in normal animals (22, 40). A previous study ex-
amined the effects of lower doses of leptin on neuroendo-
crine function in fasted mice at a time when circulating leptin
levels resembled those in the fed state (41). However, these
lower concentrations occurred 12 h after administering twice
daily injections of leptin over 48 h, which acutely raised
plasma leptin concentrations by up to 40-fold above normal
levels for several hours.
Our study examined the effect of a single injection of leptin
on food intake, and this leaves open the possibility that
physiological shifts in circulating leptin concentrations may
modulate food intake when they are sustained for a period
of time. Sustained alterations in circulating leptin concen-
trations, associated with changes in adiposity and body fat
distribution, occur with gender (42–44), with weight gain
(12) and loss (8), and over normal development (43, 44). A
recent report by Halaas et al. (45) supports the hypothesis that
sustained physiological increases in plasma leptin decrease
body weight and adiposity in normal mice. Further evidence
for a physiological role for endogenous leptin in regulating
food intake is provided by the report that icv administration
of purified antileptin antiserum increases food intake in nor-
mal rats, but not in obese Zucker rats (46).
An additional question that, until recently, has not been
addressed is whether decreases in plasma leptin concentra-
tions within the physiological range serve as a signal to
increase food intake, either acutely or chronically. Fasting (9,
10), energy restriction (11), and insulin-deficient diabetes (47)
all produce marked and sustained decrements in circulating
leptin concentrations that are probably the result of de-
creased adipocyte glucose metabolism (19). It has now been
shown that replacing leptin by osmotic minipump infusion
in streptozotocin diabetic rats, at a rate that prevents the
marked fall in plasma leptin after induction of diabetes, also
prevents the onset of diabetic hyperphagia (47, 48). In ad-
dition, there is a strong correlation between the magnitude
of the decrease in circulating leptin concentration and the
increase in hunger ratings reported during a prolonged mod-
erate energy deficit in women (49). Together, the available
data suggest a role for leptin as a long term regulator of
energy balance, rather than as a short term determinant of
appetite or satiety.
The significant and sustained suppression of food intake
in rhesus monkeys we observed after intracerebroventricular
administration of a 1 mg/kg dose of leptin indicates that, as
has been previously documented in rodents (7, 12, 19, 20),
leptin is able to act at the level of the central nervous system
to suppress food intake in primates. Thus, it is likely that in
the monkey, leptin acts in locations adjacent to the third
ventricle, areas that also appear to be involved in leptin’s
action on food intake in rodents (21, 22). Although the icv
dose of leptin employed, based on body weight, was sub-
stantially lower than the doses used in studies with icv leptin
in rodents (20, 25, 32, 33), it may have been a pharmacological
dose. Average concentrations of leptin in the CSF of healthy
human subjects are approximately 0.2–0.3 ng/mL (50, 51). It
is very likely that central administration of leptin at 1 mg/kg
produced acute elevations of CSF leptin levels far above this
concentration. However, because, like insulin (52), leptin is
likely to gain entry to the CSF compartment subsequent to
transport into the brain parenchyma, it is not possible to
determine how concentrations of a plasma hormone reach-
ing a specific brain region correlate with CSF levels of that
hormone. Thus, we can conclude that, as in rodents, centrally
administered leptin suppresses food intake in primates.
However, it is not known whether the concentrations of
leptin in the hypothalamic regions regulating food intake
were within a physiological or a pharmacological range.
There was no immediate effect of leptin administered icv
on food intake (i.e. no suppression of food intake during the
90 min after the afternoon meal provided at the same time as
leptin was administered). Rather, suppression of food intake
was first evident the following morning, 17.5 h after leptin
administration. This finding differs from studies in the rat
that have reported a suppression of food intake within 1 h of
icv leptin administration (25, 33). However, as monkeys eat
most of their meal within the first hour after meal presen-
tation, it is possible that leptin inhibits food intake much
earlier than the following morning, but given our meal feed-
ing paradigm we were unable to detect such an earlier in-
hibition. Nevertheless, unlike in the rat, icv leptin adminis-
tration did not suppress food intake within the first hour
after injection.
The delay in the effect of leptin to suppress food intake
may reflect the amount of time needed for leptin to transit
from the third ventricle to receptors within the parenchyma
of the brain. It may also reflect a multistep pathway of leptin
action on appetite. In fact, there is growing evidence that
leptin, at least in part, suppresses food intake by acting on
hypothalamic NPY neurons. The ob/ob mice with knockout of
the NPY gene are not as obese and are less hyperphagic than
ob/ob mice with an intact NPY system (53). Leptin receptor
messenger ribonucleic acid (mRNA) has been identified in
NPY-expressing neurons (23, 28), and leptin administered
icv to rats suppresses NPY synthesis (31). Leptin may also act
on hypothalamic POMC neurons to modulate food intake.
Recent evidence indicates that activation of melanocortin-3
and -4 receptors (which bind POMC-derived peptides) in-
hibits feeding in a number of rodent models of hyperphagia
(54). POMC neurons in the arcuate nucleus have been shown
to express leptin receptor mRNA in both rodents (55) and
nonhuman primates (28). The ob/ob mice have been reported
to have significantly reduced levels of POMC mRNA in the
arcuate nucleus, and leptin treatment restores POMC mRNA
to normal levels (56–58). Additionally, pharmacological
blockade of melanocortin-4 receptors has been reported to
prevent leptin-induced suppression of food intake in the rat
(59).
The effect of leptin administered icv on food intake was
apparent for more than 24 h. This finding is similar to results
reported in rats in which a single injection of leptin icv
suppressed food intake for 2–3 days, resulting in a loss of
body weight that was sustained for at least 6 days (32). The
prolonged effect of leptin administered icv on food intake
may result from a slow rate of leptin degradation within the
brain.
It is likely that the suppression of food intake subsequent
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to central leptin administration results from a specific action
of leptin, rather than from the induction of a general state of
malaise. Monkeys administered leptin icv exhibited no out-
ward signs of nausea, such as drooling, yawning, or a de-
crease in general activity. Moreover, the fact that leptin re-
sulted in a delayed, rather than an acute, inhibition of food
intake suggests that leptin was modulating food intake via
a ligand-receptor interaction, not by a nonspecific induction
of nausea or taste aversion. Additionally, leptin administra-
tion did not completely suppress feeding, but only reduced
food intake by 50–60%. This conclusion is further supported
by the work of Thiele and co-workers (33), who showed that
leptin administered icv to rats (3 mg/rat) does not cause a
conditioned taste aversion.
The finding that leptin, administered icv, led to a signif-
icant elevation in plasma norepinephrine levels provides
strong evidence that central leptin administration activates
the sympathetic nervous system. To our knowledge, this is
the first report that leptin activates the sympathetic nervous
system, as assessed by an increase in circulating norepineph-
rine levels. However, this finding supports the previously
published work of Collins and co-workers (36) in mice,
which showed that leptin increases norepinephrine turnover
in brown adipose tissue, and the more recent demonstration
in the rat that leptin activates sympathetic nerves innervating
brown adipose tissue, kidneys, hindlimb, and adrenals (37).
Moreover, peripheral administration of leptin at pharmaco-
logical doses in rhesus monkeys produces acute increases in
circulating glucose and lactate that are blocked by combined
a- and b-adrenergic blockade, demonstrating that the acute
metabolic effects of leptin in the primate are mediated by
sympathetic activation (60). It has been well documented in
rodent models that there exists an inverse relationship be-
tween activation of the sympathetic nervous system and food
intake (61, 62). To date, most substances that inhibit food
intake cause an increased activity in the sympathetic nervous
system (i.e. cholecystokinin, serotonin, etc.), and substances
that increase food intake (i.e. NPY and norepinephrine) in-
hibit the sympathetic nervous system. Thus, it is likely that
the increased sympathetic activity we have found in this
study, contributes to both the inhibition of food intake and
the leptin-induced increases in energy expenditure that have
been previously reported in mice and rats (3, 5, 22).
Interestingly, the effect of leptin on plasma norepinephrine
concentrations occurred soon after leptin administration, be-
fore leptin had any effect on food intake. Thus, the effect of
leptin to activate the sympathetic nervous system appears to
be mediated through a mechanism separate from that un-
derlying leptin-induced changes in food intake. However, it
is still possible that the effect of leptin on the sympathetic
nervous system is mediated by a leptin-induced decrease in
the activity of NPY-ergic neurons, in that NPY has been
shown to potently reduce energy expenditure via a reduction
in sympathetic output (63). Lastly, central leptin adminis-
tration did not increase plasma epinephrine concentrations.
Thus, the effect of leptin to activate sympathetic nervous
system was specific for noradrenergic sympathetic and ex-
cluded those preganglionic sympathetic nerves innervating
the adrenal medulla.
In summary, icv leptin administration causes a potent and
sustained suppression of food intake and an acute increase
in circulating norepinephrine concentrations in rhesus mon-
keys, indicating that leptin is capable of acting as a signal to
the central nervous system to modulate feeding behavior and
the level of sympathetic nervous system activity in primates.
Nevertheless, our finding that acute increases in circulating
leptin within the physiological range did not inhibit food
intake in rhesus monkeys argues against a role for leptin in
the short term control of daily fluctuations in food intake.
Rather, our data support the hypothesis that leptin serves as
a long term signal to modulate energy balance and is prob-
ably involved in regulating appetite when decreases (e.g.
insulin-deficient diabetes or prolonged energy restriction), or
increases (e.g. chronic overfeeding) of circulating leptin con-
centrations are sustained.
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